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Streptococcus agalactiae (group B Streptococcus, GBS) is a
leading cause of invasive bacterial infections in newborns, typi-
cally acquired vertically during childbirth secondary to mater-
nal vaginal colonization. Humanmilk oligosaccharides (HMOs)
have important nutritional and biological activities that guide
the development of the immune system of the infant and shape
the composition of normal gut microbiota. In this manner,
HMOs help protect against pathogen colonization and reduce
the risk of infection. In the course of our studies ofHMO-micro-
bial interactions, we unexpectedly uncovered a novel HMO
property to directly inhibit the growth of GBS independent of
host immunity. By separating different HMO fractions through
multidimensional chromatography, we found the bacteriostatic
activity to be confined to specific non-sialylatedHMOs and syn-
ergisticwith a number of conventional antibiotic agents. Pheno-
typic screening of a GBS transposon insertion library identified
a mutation within a GBS-specific gene encoding a putative gly-
cosyltransferase that confers resistance to HMOs, suggesting
that HMOsmay function as an alternative substrate to modify a
GBS component in a manner that impairs growth kinetics. Our
study uncovers a unique antibacterial role for HMOs against a
leading neonatal pathogen and expands the potential therapeu-
tic utility of these versatile molecules.
Group B Streptococcus (GBS)2 are Gram-positive bacteria
that colonize the vaginal epithelium in 15–30% of healthy
women. GBS transmission to the newborn is associated with
risk of pneumonia, septicemia, and meningitis (1–3). In the
United States and other developed countries, implementation
of universal antenatal GBS culture screening and administra-
tion of intrapartum antibiotic prophylaxis has reduced GBS
incidence in the first few days of life; however, it has not had a
similar impact on late-onset infections, which now represent
approximately one-third of total cases (4). Up to half of all
infants with late-onset GBS also developmeningitis, which car-
ries a high incidence (40%) of neurocognitive sequelae among
survivors (5). In a recent meta-analysis, the overall incidence of
GBS infection in infants3months of age in the Americas and
Europe is 0.53–0.67 cases/1000 births, with an overall case
fatality rate of 7–10% (6). The emergence of antibiotic-resistant
GBS strains has become an increasing concern (1, 7, 8).
Human milk oligosaccharides (HMOs) are a group of com-
plex carbohydrates that are highly abundant in human milk
(10–15 g/liter) but not in infant formula (reviewed in Ref. 9).
HMOs are comprised of fivemonosaccharides: D-glucose (Glc),
D-galactose (Gal), GlcNAc, L-fucose, and sialic acid (N-acetyl-
neuraminic acid). The Gal-Glc disaccharide (lactose) backbone
can be further elongated by up to 15 Gal-GlcNAc repeats and
can be sialylated or fucosylated. Over 150 structurally dis-
tinct HMOs have been identified, comprised of neutral (non-
sialylated) and acidic (sialylated) forms, and the amount and
composition are highly variable between women (reviewed
in Ref. 10).
HMOs are not digested by the infant and reach the colon
intact, where they serve as metabolic substrates for specific,
potentially beneficial bacteria and help shape the infant micro-
biome. HMOs also act as soluble receptor decoys to prevent
attachment of microbial pathogens to the host (11–14). HMOs
are partially absorbed and reach the systemic circulation of the
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infant (15, 16) and appear intact in the urine of breast-fed
infants (17, 18), with the potential to exert effects in organs
other than the gut and including the urinary tract.Most intrigu-
ingly, HMOs also appear in the urine of pregnant women as
early as the end of the first trimester (19), suggesting that
HMOs might already affect pregnant women and the growing
fetus long before birth.
In a previous study, we demonstrated that HMOs regulate
the host innate immune response in bladder epithelial cells
to prevent invasion and cytotoxicity caused by uropathogenic
Escherichia coli (UPEC) without any direct interference with
bacterial growth (20). To delineate whether HMOs generate
similar effects with other neonatal pathogens, we examined
the effect of HMOs on GBS, which is commonly found in the
urogenital tract of pregnant women. Unexpectedly, we found
that HMOs directly inhibit the growth of GBS, a property not
shared with UPEC, Pseudomonas aeruginosa, or Staphylo-
coccus aureus. Further investigation revealed a unique aspect
of HMOs that causes a significant GBS growth defect.
Results
Humanmilk oligosaccharides inhibit growth of group B
Streptococcus
To evaluate the potential antimicrobial effect(s) of HMO on
a group of bacterial pathogens, we resuspended 105 cfu of
each bacterial overnight culture in serum-free tissue culture
medium (RPMI) with or without 2 mg/ml of HMOs isolated
from pooled human milk (pHMO) and then incubated for 4 h.
pHMOs did not affect the growth of UPEC, P. aeruginosa, and
methicillin-resistant S. aureus. However, growth of the GBS
test strain (serotype III isolate COH1) was reduced by10-fold
(p  0.05) (Fig. 1A). We confirmed that HMOs are bacterio-
static and not bactericidal because they did not kill GBS even at
very high concentration (Fig. 1B). pHMO impaired the growth
of the threemost commonGBS serotypes—serotypes III (strain
COH1), Ia (strain A909), and V (strain NCTC10/84)—in a
dose-dependent manner between 0.25–1.0 mg/ml (Fig. 1C).
The neutral fraction of HMOs possesses the GBS inhibitory
activity
Galacto-oligosaccharides (GOS) are sometimes used to sup-
plement infant formula to mimic the prebiotic properties of
HMOs. However, GOS are structurally different from HMOs
and consist of linear chains of two to six galactose residues
linked to a single glucose. Unlike pHMOs, GOS did not impact
GBS growth (Fig. 2A). Moreover, pHMOs pretreated with pro-
teinase K retained their GBS-inhibitory activity (supplemental
Fig. S1). Thus, pHMO-mediated inhibition of GBS growth is
neither a nonspecific effect of oligosaccharides nor does it
appear to require a protein.
Next, we separated pHMOs into sialylated, acidic HMOs
(aHMOs) and non-sialylated, neutral HMOs (nHMOs) (9).
Although nHMOs exerted a similar effect as pHMOs, aHMOs
did not inhibit GBS growth (Fig. 2B). Consistent with this
result, sialidase treatment of pHMOs to remove sialic acidmoi-
eties, which was confirmed by HPLC analysis, did not alter the
inhibitory properties (Fig. 2C). At 1.0 mg/ml, nHMOs slowed
serotype III GBS (COH1) growth by 98.2%, serotype Ia GBS
(A909) growth by 97.0%, and serotype V GBS (NCTC10/84)
growth by 96.0% (Fig. 2D). At a lower dose of 0.25 mg/ml,
nHMOs inhibited growth of the serotype III and Ia GBS strains
Figure1.Humanmilkoligosaccharides inhibitGBSgrowth.A, bacteriawere cultured for 4 h in SF-RPMI in the absence (solid lines) or presence (dashed lines)
of pHMO in a 37 °C, 5% CO2 incubator. Pa, P. aeruginosa;MRSA, methicillin-resistant S. aureus; GAS, group A Streptococcus. B, GBS serotype III strain COH1 was
incubated with 1–10 mg/ml of pHMO in SF-RPMI. C, growth of three GBS strains of differing serotypes in the presence of pHMOs at the indicated concentra-
tions. Relativegrowth represents cfu at the indicatedpointwith respect to initial cfu inoculum100%. Solid line, nopHMOs;dotted line, withpHMOs; error bars,
S.E. (n 3). *, p 0.05, one-way ANOVA, Tukey’s multiple comparison’s test.
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by more than 40-fold (p  0.01), an effect more potent than
pHMOs at the same dose (Fig. 1C).
Identification of neutral HMOs that inhibit GBS growth
To identify specific neutral oligosaccharide(s) responsible
for GBS-inhibitory activity, we separated nHMOs into 10 frac-
tions via size exclusion chromatography.We evaluated the bac-
teriostatic activity of each fraction by monitoring the GBS
growth rate and found the strongest growth inhibition in the
fourth and sixth size fractions (Fig. 3A). Based on HPLC pro-
files, these fractions primarily contained HMOs with up to
eight monosaccharide moieties. Based on this lead, we selected
nine commercially available oligosaccharides, each with slight
modifications in the core structure known to exist in HMOs:
lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-
neohexaose (LNnH), lacto-N-fucopentaose I (LNFPI), lacto-N-
difucohexaose II (LNDFHII), lacto-N-neooctaose (LnNO),
lacto-N-neodifucohexaose (LNnDFH), lacto-N-neofucopen-
taose (LNnFPV), and lacto-N-fucopentaose V (LNFPV). GBS
were challenged with 5 mg/ml of these individual oligosaccha-
rides, and growth was observed to be significantly (60–70%)
inhibited by LNT and its fucosylated derivative LNFPI (Fig. 3B).
Most intriguingly, the LNT structural isomer LNnT (Fig. 3C)
showed no significant inhibition of GBS growth.
Disruption of GBS glycosyltransferase leads to resistance
against HMOs
To identify bacterial factors involved in GBS susceptibility to
HMOs, we screened 1200 serotype III GBS (COH1) trans-
poson Tn917Emutants from our previously published library
(21) for resistance to growth suppression by 2.5 mg/ml of
pHMOs. This screen selected for a candidate mutant that
exhibited normal growth over 7 h despite exposure to pHMOs
(Fig. 4A). Through chromosomal sequence analysis, we identi-
fied the transposon insertion in this mutant to lie in the pro-
moter of a gene annotated as gbs0738. Based on the Basic Local
Alignment Search Tool (BLAST), gbs0738 encodes a putative
glycosyltransferase that belongs to the carbohydrate-active
enzymes (CAZY) GT-8 family and is conserved among 18
group B Streptococcus subspecies, with high levels of identity
(99%) in strains, including serotype Ia A909 and serotype V
NCTC10/84 (supplemental Fig. S2). To confirm that the trans-
poson Tn917E insertion was not accompanied by unlinked
mutations in the genome, we created a targeted in-frame inser-
tion mutant in the wild-type strain COH1 to create knockout
strain 0738. The targeted 0738 mutant recapitulated the
growth profile of the original transposon mutant and was not
susceptible to the bacteriostatic effect of pHMO (p 0.05) (Fig.
4, B and C). This finding confirms that the resistance to HMOs
is specifically linked to inactivation of the gbs0738 gene.
Of note, the GT-8 glycosyltransferase shares some sequence
homology with LPS glycosyltransferase RfaJ, an important
outer membrane biosynthesis protein in Gram-negative bacte-
ria (22). Because GBS is a Gram-positive pathogen lacking an
outer membrane, we postulated this glycosyltransferase could
promiscuously catalyze the glycosylation of HMOs into poly-
saccharide components of the GBS capsule or incorporate
them into peptidoglycan/glycan-binding proteins (i.e. lectins)
in the GBS cell wall. To explore this hypothesis, we first moni-
tored the growth kinetics of a GBS serotype III capsule-defi-
cient mutant (strain HY106 (23)) in the presence of HMOs.We
Figure 2. The neutral fraction of humanmilk oligosaccharides exerts a bacteriostatic effect on GBS. A, GBS serotype III strain COH1 growth curve in the
presence of 5 mg/ml of pooled HMOs or GOS in SF-RPMI medium. B, GBS growth in SF-RPMI supplemented with pHMO, nHMO, or aHMO. C, GBS growth in
untreated pooled HMO (open circles) or sialidase-treated pooled HMO (closed circles). D, GBS strain COH1, A909, and NCTC growth in the presence of neutral
HMO fractions at the indicated concentrations. Relative growth represents cfu at the indicatedpointwith respect to initial cfu inoculum 100%. Error bars, S.E.
(n 3). ***, p 0.001; **, p 0.01; *, p 0.05; ns, not significant; one-way ANOVA, Tukey’s multiple comparison’s test or Dunnett’s post-test.
Humanmilk oligosaccharides inhibit GBS growth
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found that the capsule-deficient mutant still exhibited signifi-
cant growth inhibition in the presence of nHMO (Fig. 4D), sug-
gesting that the capsule is not targeted by nHMOs. To delineate
whether GBS sensitivity to HMOs extends to the activity of
other glycosyltransferases, we studied a GBS mutant (iagA)
encoding a group 1 glycosyltransferase (21) that likewise
remained sensitive to nHMO-mediated inhibition (Fig. 4D).
Thus, our results suggest that GBS susceptibility to nHMOs
is attributed with some specificity to the gbs0738-encoded
glycosyltransferase.
Synergistic activity of HMOs and antibiotics against GBS
In serious or difficult-to-treat infections, combination anti-
biotic therapy is often considered to exploit synergistic activi-
ties and to reduce the risk of generating antimicrobial resis-
tance. We examined whether prior exposure to HMOs could
Figure 3. Identification of neutral HMO fraction(s) that blockGBS growth. A and B, nHMOswere separated by size exclusion chromatography. A, a total of
10 fractions were isolated from 40 mg/ml neutral HMO. Relative growth of GBS within 2 h in each fraction (N1-N10 and RPMI as a control) is shown as A600 nm
4 h/2 h, which represents the ratio of optical densitymeasured at 4 h divided by the optical densitymeasured at 2 h. B, relative GBS growth (cfu recoveredwith
respect to initial inoculum) after 2 h of incubation in SF-RPMI alone (red columns) or supplemented with 5 mg/ml of individual commercially acquired neutral
oligosaccharides (black columns). Relative growth represents cfu at indicatedpointwith respect to initial cfu inoculum 100%. *,p 0.01; **, p 0.01; ***, p
0.001; one-way ANOVA, Tukey’s post-test. C, structures of LNT, LNnT, and LNFPI. Blue circles, glucose; yellow circles, galactose; blue squares, N-acetyl-glucosa-
mine; red triangle, fucose.
Figure 4. A GBS glycosyltransferase mutant is not susceptible to HMO-mediated killing. A, transposon library screening identified a mutant GBS that is
resistant to HMO treatment. 100l of GBS COH-1 (A600 0.01) is grown in SF-RPMI supplementedwith 5mg/ml of pHMO for 24 h at 37 °C. A600 wasmeasured
at 30-min intervals over 8 h through a Bioscreen CMBR system. Tn, transposon. B, growth curves of GBS COH1WT (black) or 0738 targeted knockout (red) in
serum-freeRPMImedia (solid lines) orwith 5mg/mlpHMO (dotted line) over 8hat 37 °C.C, relativeGBSgrowthafter 4hof incubation in SF-RPMIwithorwithout
5mg/ml of pHMO.D, growth curves of GBS COH1WT (black), HY106 (red) andiagA (blue) in SF-RPMI (solid lines) or with 5mg/ml of neutral HMO (dotted lines).
Relative growth represents cfu at the indicated point with respect to initial cfu inoculum 100%. ***, p 0.001; ns, not significant.
Humanmilk oligosaccharides inhibit GBS growth
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sensitize GBS to different pharmaceutical antibiotics. GBS
growth was monitored over 4 h at different concentrations of
nHMOs, and the IC50 was determined to be 0.899 mg/ml (Fig.
5A). We then measured the IC50 of GBS in the presence or
absence of 0.25mg/ml, a sub-IC50 of nHMOs, in the presence of
the glycopeptide antibiotic vancomycin, the fluoroquinolone
antibiotic ciprofloxacin, or the -lactam antibiotic imipenem.
The presence of nHMOs at a sub-IC50 concentration dramati-
cally reduced the IC50 of both vancomycin (0.25 g/ml alone
versus 0.00602 g/ml with nHMOs) and ciprofloxacin (1.37
g/ml alone versus 0.0021g/mlwith nHMOs) (Fig. 5,B andC)
but did not improve the activity of imipenem (supplemental
Fig. S3). Calculation of the interaction index (Fig. 5D) revealed
the interaction between nHMO and vancomycin or ciprofloxa-
cin to represent true synergism (I 0.5).
Discussion
A growing body of evidence has documented a variety of
protective properties of HMOs against infectious agents. In
additiontomodulatinghostimmuneresponses(24,25),oligosac-
charides can pose as receptor decoys to prevent adhesion of
microbial pathogens to epithelial surfaces (11–14). In a prior
study, we demonstrated that HMOs, specifically the sialylated
fraction of HMOs, and 3-sialyllactose (3SL) alone, support
host innate defense and reduce invasion of UPEC into bladder
epithelial cells. Conversely, in this study we found that certain
neutral, non-sialylated forms of HMOs may cause a significant
defect in GBS growth. To our knowledge, this is the first study
to associate HMOs with a direct antimicrobial effect. Among
the four bacterial species tested, the bacteriostatic effect of
HMOs was unique to GBS.
Through a combination of mutation and bioinformatics
analysis, we identified a conserved putative glycosyltransferase
family 8 member (gbs0738) that is required for GBS sensitivity
to HMOs. The predicted protein product of this GBS glycosyl-
transferase does not possess strong identity or similarity to
genes from other bacterial species, which may explain why
HMO inhibition is specific to GBS and not to other tested
organisms (Fig. 1A). This particular family of glycosyltrans-
ferases is characterized by the GT-A fold and DXD motif. The
GBS enzyme (gbs0738) shares high identity with an E. coli
enzyme within this family of glycosyltransferases that is
involved in synthesis of the outer core region of lipo-oligosac-
charide, catalyzing the -1,2 linkage of donor sugar to their
acceptors (26). In Streptococcus spp., glycosyltransferases par-
ticipate in the biosynthesis of capsular polysaccharides, cell wall
peptidoglycan, and anchoring of lipotechoic acidwithin the cell
wall (27, 28). In GBS, glycosyltransferase-encoding cpsE is
important for the synthesis of the surface polysaccharide cap-
sules (29), and iagA is a glycosyltransferase that aids in the
anchoring of lipotechoic acid (21), but neither are essential for
GBS growth (21, 29). GBS mutants lacking capsule or IagA,
however, remain sensitive to HMOs. Our results suggest that
growth inhibition by HMOs may depend on gbs0738-encoded
glycosyltransferase to catalyze incorporation of HMO compo-
nents into the cell wall. Ongoing work aims to biochemically
characterize this glycosyltransferase and identify specific HMO
substrates and GBS targets.
LNT causes the highest inhibition of GBS growth (Fig. 3B).
LNT is one of themost abundant core structures in humanmilk
(0.5–1.5 g/liter in mature human milk) (30). Further, LNT has
Figure 5. Neutral HMOs increase GBS sensitivity to antibiotics. A, IC50 curve of nHMOs. Cfu were recovered after 4 h of nHMO treatment at different
concentrations. B and C, IC50 curves of vancomycin (B) and viprofloxacin (C) in the presence (red) or absence (black) of 0.25 mg/ml of nHMOs that show GBS
growth inhibition. Error bars, S.E. (n 3). D, the interaction index calculation formula.
Humanmilk oligosaccharides inhibit GBS growth
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been identified to block Entamoeba histolytica binding to epi-
thelial cell surfaces (12). However, LNT has never been pro-
posed to serve any direct antimicrobial function. One intrigu-
ing observation is that a slight conformational change of the
single 3GlcNAc1 residue of LNT to 4GlcNAc1 in LNnT
nearly abrogates its bacteriostatic effect on GBS (Fig. 3B). Our
results suggest that there is a strict 3GlcNAC1 conformation
requirement for maximal GBS inhibition.
HMOs have been found in the plasma (15, 16) and urine (17,
18) of breast-fed infants. Also, HMOs appear in the urine of
pregnant women as early as the end of first trimester. Although
the exact concentration of HMOs present in these areas is still
uncertain, our results support the notion that lower incidences
of GBS infections in breast-fed infants and already in pregnant
women could include a contribution from the antibacterial
properties of HMOs. Further, our demonstration of HMO syn-
ergism with certain pharmaceutical antibiotics suggests their
potential utility in adjunctive therapy of GBS infection. Future
animal studies as well as human cohort studies on human
mother-infant dyads may help identify associations of individ-
ual HMOs like LNT with GBS infection risk. It is intriguing to
envision the rational development of novel anti-infective strat-
egies based on the natural template of human milk.
Experimental procedures
Bacterial strains, cells, media, and growth conditions
The wild-type GBS strain COH1 (serotype I and I) and its
mutant derivatives HY106 and iagA (21), A909 (serotype Ia),
NCTC10/84 (serotype V), and methicillin-resistant S. aureus
strain TCH1516 were grown overnight in Todd-Hewitt agar or
Todd-Hewitt broth (THB). P. aeruginosa strain PA14 and
UPEC strain CFT073 (O6:K2:H1, ATCC 700928) were grown
overnight in Luria-Bertani agar or broth. All bacteria were
propagated in standing culture to stationary phase at 37 °C in
5% CO2 unless stated otherwise.
Humanmilk oligosaccharide isolations
pHMOs were prepared as described previously (31) and
lyophilized for long-term storage. Milk from 36 different
donors was pooled to account for heterogeneity in HMO com-
position between different women. The human milk donation
program has been reviewed by the Institutional Review Board
(IRB) Chair at University of California, San Diego and certified
as exempt from IRB review under 45 CFR 46.101(b), category 4
because subjects cannot be identified and linked to generated
data. Pooled HMOs were separated into aHMO and nHMO by
anion exchange chromatography as described previously (31).
nHMOs were further separated by size using size exclusion
chromatography. pHMOs were disialylated by incubation with
neuraminidase from Vibrio cholerae. HMO composition was
analyzed by high-performance liquid chromatography and
mass spectrometry.
Sources of galacto-oligosaccharides and purified glycans
Galacto-oligosaccharides were generously provided by Frie-
sland Campina Domo (the Netherlands). Purified glycans were
purchased from ELICITYL OligoTech, which includes LNT,
LNnT, LNnH, LNFPI, LNDFHII, LnNO, LNnDFH, LNnFPV,
and LNFPV.
GBS growth and susceptibility test
Overnight GBS growth was back-diluted to A600  0.01 in
serum-free RPMI 1640 (SF-RPMI) (Life Technologies) or sup-
plemented with pooled or fractions of HMOs. To measure
growth, bacteria were grown in 100 l of medium at 37 °C. At
600 nm, absorbance was recorded at 30-min interval using the
BioScreen instrument (GrowthCurves USA). To detect growth
in cfu, bacteria were grown in 100 l of medium at 37 °C in
humidified air with 5% CO2 over 2 or 4 h. Recombinant pro-
teinase K (Roche) was used at 0.1 mg/ml.
GBS COH-1 transposon library
The transposon library was constructed as described previ-
ously (21). To screen for mutants resistant to HMOs, we nor-
malized overnight cultures of transposon mutants to A600 of
0.1. Approximately 10l of eachmutant was cultured in 100l
of SF-RPMI supplemented with 5 mg/ml of pooled HMOs.
Growth was monitored over an 8-h period at 37 °C by measur-
ing optical density at 600 nm at a 30-min interval using a Bio-
screen C MBR system.
GBS COH-10738 construct
To generate a targeted knockout, we cloned the gbs0738
gene to the temperature-sensitive vector PHY304. Briefly,
gbs0738 was PCR-amplified with primers XhoI-gbs0738F (5-
CGATCTCGAGTGCTCAGGCACCTACAACTG-3)	 Hin-
dIII-gbs0738R (5-CAGTAAGCTTAGCAGGCAAGTTCAT-
CAAGAG-3) to generate a 300-bp amplicon. The purified
PCR amplicon was digested with XhoI and HindIII and ligated
into previously digested pHY304. The construct was cloned
into E. coli DH5 and isolated by mini-prep. Approximately 1
g of PHY304-gbs0738 DNA was transformed into electro-
competent GBS at 1550 V. The transformed bacteria were
allowed to recover in 500l of THBwith 0.25M sucrose at 30 °C
for 2 h while shaking at 220 RPM. Bacteria were grown over-
night on Todd-Hewitt agar 	 2 g/ml erythromycin at 30 °C.
After 2–3 days, colonies were selected and inoculated into 5 ml
of THB 	 5 g/ml erythromycin at 30 °C overnight. The next
day, cultures were prepared in duplicate in THB	 erythromy-
cin at 30 °C and 37 °C to select for bacteria with the targeting
vector incorporated into the chromosome. Resultant single col-
onies from the 37 °C culture were isolated and confirmed for
single crossover mutation by PCR using primers M13F (5-
GTTTTCCCAGTCACGAC-3) and gbs0738R2 (5-ACACG-
CTCCTCCTTTGATATT-3). Wild-type GBS had an ex-
pected 1.67 kb PCR product, whereas the mutant had an
expected 6.5-kbp PCR product.
Statistical analysis
All experiments were performed in triplicate or quadrupli-
cate and repeated in at least two independent experiments.
Error bars represent S.E. (n  3) from multiple independent
experiments. Statistical analysis was performed using Student’s
unpaired two-tailed t test or one-way ANOVA for multiple
comparisons (GraphPad Prism version 5.03). *, p 0.05; **, p
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0.01; and ***, p  0.001 represent statistical significance. p 
0.05 represents non-significance. IC50 was calculated using
non-linear regression curve fit using the equation log (inhibi-
tor) versus response-variable slope. Error bars represent S.E.
(n 3).
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